MIM
ACRS icon

Monashee Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

Monashee Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.88M Buy
+500,000
New +$1.69M 1.02% 33
2025
Q2 		– Sell
-888,888
Closed -$1.36M – 58
2025
Q1 		$1.36M Hold
888,888
– – 0.16% 45
2024
Q4 		$2.2M Buy
+888,888
New +$2.21M 0.3% 27
2021
Q3 		– Sell
-100,000
Closed -$1.76M – 266
2021
Q2 		$1.76M Buy
+100,000
New +$2.27M 0.21% 141
2017
Q4 		– Hold
0
– – – 61
2017
Q3 		– Sell
-45,740
Closed -$1.23M – 43
2017
Q2 		$1.24M Buy
+45,740
New +$1.24M 0.52% 51
2017
Q1 		– Sell
-126,700
Closed -$3.65M – 56
2016
Q4 		$3.44M Buy
+126,700
New +$3.23M 1.67% 23
2016
Q3 		– Hold
0
– – – 64
2016
Q2 		– Hold
0
– – – 18

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Monashee Investment Management's ACRS Position: Q1 2026 in Review

Monashee Investment Management opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 500,000 shares worth $1.88M. The stake represents 1.02% of the portfolio and ranks #33 among its holdings. This is a return to the name: Monashee Investment Management previously reported a position in ACRS as recently as Q1 2025.

Monashee Investment Management first reported a position in ACRS in Q4 2016 and has held it in 6 quarters since. The position peaked at $3.44M in Q4 2016. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Monashee Investment Management held 500,000 shares of Aclaris Therapeutics worth $1.88M as of Q1 2026.
  • Aclaris Therapeutics was a new Monashee Investment Management position in Q1 2026.
  • Aclaris Therapeutics made up 1.02% of Monashee Investment Management's portfolio in Q1 2026, its #33 holding.
  • Monashee Investment Management first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 6 quarters since.
  • Monashee Investment Management's Aclaris Therapeutics position peaked at $3.44M in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.